Article about antibiotics and Novartis's decision to pull out. They specifically mention how this is leaving the space wide open for smaller biotechs. The remind us of the Cubist buyout, for the modest fee of $9.5 billion , and end with this fascinating item:

Quote:

---

FDA Commissioner Scott Gottlieb published proposals last month to incentivize biopharma investment in antibiotic R&D , including a pull mechanism in which hospitals would pay a fixed licensing fee in return for access to a set number of annual doses of a new antibiotic, rather than reimbursing on a per-use basis.

---

https://www.fiercebiotech.com/biotech/despite...d=48083647